OpGen Inc (OPGN)

[mick]

Following approval from both OpGen and Curetis shareholders, the merger between the two companies has now closed.


Curetis is a Germany-based molecular diagnostics company with a focus
on infectious disease. It has two main business lines:


the Unyvero A50 high-plex polymerase chain reaction (PCR) platform for
the diagnosis of infectious disease in hospital patients;


and the ARES AMR database (ARESdb), which includes data on 40,000
sequenced strains with a focus on resistant pathogens.


Together, OpGen and Curetis had around $6.0m in sales in 2019,
up 33% compared to the combined sales of the previous year and
at the top end of the original $5–6m guidance for 2019
(given at the time of the merger announcement).